International Chinese Musculoskeletal Research Society (ICMRS) is pleased to announce the first inaugural scientific awards to our members who have made outstanding contributions to their scientific and professional career in musculoskeletal science and medicine.
2023 Lifetime Achievement Award
The ICMRS Lifetime Achievement Award is to honor a scholar who has devoted much of his/her career to the advancement in musculoskeletal science and medicine. Throughout their career the awardee has demonstrated the scientific excellence in research and innovation and provided mentorship and in their leadership, service, education, and professional relationships. This prestigious award honors an individual who is a basic researcher and/or clinician in the field of musculoskeletal medicine.
Prof. Kerong Dai, MD, Academician of Chinese Academy of Engineering at Shanghai Jiao Tong University School of Medicine
The ICMRS Lifetime Achievement Award has been honored to Prof. Dai Kerong Dai, MD, Academician of Chinese Academy of Engineering at Shanghai Jiao Tong University School of Medicine, who has made substantial contributions in the areas of medical application of Orthopedic Biomechanics, 3D Bioprinting, Stem Cell Engineering, Arthroplasty, and Osteoporosis. He has published more than 500 papers as first author and co-author and books as editor-in-chief or contributor, and also have been honored with 45 prizes including Chinese National Invention Prize, National Science and Technology Prize, etc. He is the chief scientist of Shanghai Medical 3D Printing Innovation Research Center. He and his team have carried out a series of basic and clinical research on stem cell technology to promote bone regeneration and participated in the invention and translation of related research into clinical application (NMPA 20213101079). The 3D printing center also witness the China first registration certificate for 3D printed personalized artificial bone joint prosthesis (NMPA 3050065: 2003) and the world’s first 3D printed bioactive bone grafts for clinical application.
2023 Distinguished Clinical Investigator Award
The Distinguished Clinical Investigator Award is awarded to a clinical scientist making outstanding contributions to the field of clinical management of musculoskeletal diseases including surgical management and therapeutics, epidemiology and health-services research and clinical outcomes. The awardees should be established Investigators who are at the full professor level. This research should have been conducted within the last five years.
Prof. Qing Jiang, MD, PhD, at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
The Distinguished Clinical Investigator Award has been honored to Professor Qing Jiang, MD, PhD, at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, who is Orthopedic consultant who has been practicing medicine for 34 years and performed more than 20,000 surgeries and treated more than 100,000 patients. He had been engaged in orthopedic and sports medicine clinical and basic research since 1989. Prof. Jiang Mainly engaged in the basic and clinical research of sports system diseases, and published 243 Chinese core articles, 289 SCI articles, included Nature Medicine, Nature Genetic, Nature Communications, Cell Metabolism, PNAS, Annals of the Rheumatic Diseases, Science Translational Medicine, Advanced Materials, ACS NANO etc. Prof. Jiang is the editorial board member of several SCI magazines, include BMC musculoskeletal disorders, Osteoarthritis and Cartilage and Orthopedic Surgery, and created an English magazine Annals of Joint as the chief editor. He led the preparation of the guidelines for the diagnosis and treatment of osteoarthritis, and also participated in the preparation of several domestic orthopedics guides and was invited to give lessons in Australia and Japan for many times.
2023 Distinguished Translational Research Investigator Award
The Distinguished Translational Research Investigator Award is awarded to a scientist and/or clinician who has made outstanding contributions and impact to the field of musculoskeletal research by translating a research concept or idea into clinical application. The awardees should be established Investigators who are at the full professor level. Considering the length of research translation from concept to product approval or clinical trial normally takes a long time, there will be no limit on when the research is conducted.
Dr Hua Zhu (David) Ke, Founder and CEO, Angitia Biopharmaceuticals
The Distinguished Translational Research Investigator Award has been honored to Dr Hua Zhu (David) Ke, Founder and CEO, Angitia Biopharmaceuticals, who has dedicated all his efforts on the discovery and development of innovative drugs for treatment of serious musculoskeletal diseases for the last 30 years. Before founding Angitia in 2018, David served as Vice President and the Head of Bone Therapeutic Area in UCB Pharma in the United Kingdom, and Scientific Executive Director and Head of Bone Research in Amgen Inc. in the United States, and Research Fellow and Head of Bone Pharmacology in Pfizer Central Research and Development in the United States. As one of the major contributors, David led his teams to the successful discover and development of blockbuster innovative drugs for treatment of serious bone diseases that have been launched in United States, Europe, Japan, China, and other parts of the world. These innovative drugs included Prolia (osteoporosis), Xgeva (bone metastases) and Evenity (osteoporosis).
2023 Distinguished Basic Research Investigator Award
The Distinguished Clinical Research Investigator is awarded to a basic scientist who has made outstanding contributions to the field of musculoskeletal research in all areas of basic science including biology, bioengineering and biomaterials. The awardees should be established. Investigators who are at the full professor level. This research should have been conducted within the last five years.
Prof. Xu Cao, PhD at Johns Hopkins University
The Distinguished Clinical Investigator Award has been honored to Professor Xu Cao, PhD at Johns Hopkins University, who has strived to discover the fundamental mechanisms of bone biology to gain a deeper understanding of major musculoskeletal disorders and develop potential therapies for these bone diseases. We have revealed the coupling mechanism of bone remodeling in the maintenance of bone homeostasis, in which TGF-β activated by osteoclasts induces migration of mesenchymal stem cells to bone resorptive sites for bone formation. The recruited mesenchymal stem cells then undergo differentiation for bone formation. The coupled bone remodeling by TGF-β is associated with angiogenesis. Alterations in the coupling process in bone remodeling leads to many skeletal diseases. Our research in those fields has been published in Cell Stem Cell, Nat Med., Nat Commun., J Clin Invest. etc. We have organized and planned several clinical trials to investigate topics such as stem cell recruitment in anabolic versus antiresorptive osteoporosis therapy. We have also screened and synthesized a series of small molecules for osteoarthritis and spine disc degeneration. Our goal is to create effective disease-modifying therapies to treat osteoarthritis, spine disc generation, and other major skeletal diseases.
Minghao Zheng, MD, PhD, President of ICMRS (2021-2023)
Medical School, The University of Western Australia, WA, 6009
Minghao.zheng@uwa.edu.au
